 WASHINGTON, Aug. 3, 2021 PRNewswire -- Vanda Pharmaceuticals Inc. Vanda Nasdaq: VNDA today announced that enrollment has closed in the ODYSSEY study comparing tradipitant and placebo in hospitalized COVID-19 pneumonia patients. Enrollment was closed because the study met the pre-defined futility criteria, indicating that the study was unlikely to succeed in its pre-specified primary endpoint. 